<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381679</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-205</org_study_id>
    <nct_id>NCT01381679</nct_id>
  </id_info>
  <brief_title>Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)</brief_title>
  <acronym>ACT II</acronym>
  <official_title>Austrian Cholesterol Screening And Treatment II (ACT II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol
      Screening and Treatment project (ACT I), which assessed the cholesterol status, including
      achievement of the target levels applicable at that time (LDL levels &lt;100 mg/dL), in
      participants with coronary heart disease (CHD) already being treated with a statin. In this
      study, participants without adequate LDL-cholesterol reduction with a statin underwent
      extension of therapy with ezetimibe with the goal of achieving target levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Individual LDL-C target values were set according to the Austrian Cholesterol Consensus (ACC) 2007 for patients for patients suffering from coronary heart disease (CHD) or CHD equivalent in an office-based, routine medical care setting. Participants were categorized as either high-risk or very high-risk based on ACC criteria. The LDL-C target levels for each category were 100 mg/dL and 70 mg/dL, respectively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol (TC) at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TC at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HDL-C at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides (TG) at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TG at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1682</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>Participants in whom LDL-C target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants without adequate LDL-cholesterol reduction with a statin, representative
        cross-section across all regions/parts of Austria (federal provinces, urban/rural areas,
        office-based internists/general practitioners)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participants in whom LDL-cholesterol target levels have not been achieved.

          -  Participants in whom a decision has been made by the physician to initiate treatment

        with ezetimibe (longitudinal analyses). The treatment decision will be made prior to

        and independent from inclusion of participants into this study.

        - Participants with LDL cholesterol levels â‰¤113 mg/dl and a very high risk, which led to
        case-by-case approval of medication may be documented.

        Exclusion criteria:

          -  Any condition which, in the opinion of the treating physician, precludes treatment
             with ezetimibe.

          -  In order not to interfere with data collection it is recommended not to include
             participants currently in a clinical trial.

          -  Previous and ongoing treatment with ezetimibe.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>November 23, 2011</results_first_submitted>
  <results_first_submitted_qc>February 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2012</results_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1682"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="794"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="888"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="885"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1682"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.58" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Females</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level</title>
        <description>Individual LDL-C target values were set according to the Austrian Cholesterol Consensus (ACC) 2007 for patients for patients suffering from coronary heart disease (CHD) or CHD equivalent in an office-based, routine medical care setting. Participants were categorized as either high-risk or very high-risk based on ACC criteria. The LDL-C target levels for each category were 100 mg/dL and 70 mg/dL, respectively</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level</title>
          <description>Individual LDL-C target values were set according to the Austrian Cholesterol Consensus (ACC) 2007 for patients for patients suffering from coronary heart disease (CHD) or CHD equivalent in an office-based, routine medical care setting. Participants were categorized as either high-risk or very high-risk based on ACC criteria. The LDL-C target levels for each category were 100 mg/dL and 70 mg/dL, respectively</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol (TC) at Month 3</title>
        <time_frame>Baseline and Month 3</time_frame>
        <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for TC.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol (TC) at Month 3</title>
          <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for TC.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="782"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.6" spread="40.5" lower_limit="-49.4" upper_limit="-43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TC at Month 12</title>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for TC.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TC at Month 12</title>
          <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for TC.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="782"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.5" spread="37.62" lower_limit="-57.7" upper_limit="-51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Month 3</title>
        <time_frame>Baseline and Month 3</time_frame>
        <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for LDL-C.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Month 3</title>
          <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for LDL-C.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="750"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.7" spread="31.81" lower_limit="-44.2" upper_limit="-39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Month 12</title>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for LDL-C.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Month 12</title>
          <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for LDL-C.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="750"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.3" spread="26.64" lower_limit="-51.9" upper_limit="-46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Month 3</title>
        <time_frame>Baseline and Month 3</time_frame>
        <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for HDL-C.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Month 3</title>
          <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for HDL-C.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="774"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="14.17" lower_limit="2.0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HDL-C at Month 12</title>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for HDL-C.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HDL-C at Month 12</title>
          <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for HDL-C.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="774"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="15.05" lower_limit="3.1" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides (TG) at Month 3</title>
        <time_frame>Baseline and Month 3</time_frame>
        <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for TG.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides (TG) at Month 3</title>
          <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for TG.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="756"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.8" spread="82.51" lower_limit="-41.1" upper_limit="-26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TG at Month 12</title>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for TG.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TG at Month 12</title>
          <population>Participants with baseline, follow-up visit 1 (3 months), and follow-up visit 2 (12 months) measurements for TG.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="756"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.9" spread="75.06" lower_limit="-51.5" upper_limit="-36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Participants in whom low density lipoprotein cholesterol (LDL-C) target levels have not been achieved and for whom ezetimibe therapy has been chosen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1682"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1682"/>
              </event>
              <event>
                <sub_title>Bronchial Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1682"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1682"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

